Physician profile
Michael E Belete
NPI 1811075328
$1,321.21
in general payments reported to CMS, 2019-2025
25 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $195 · 2021: $276 · 2022: $20.88 · 2023: $16.04 · 2024: $117 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $197.52 | 2019-2025 | Airsupra |
| Abbvie INC. | $186.98 | 2019-2025 | Vraylar |
| Novo Nordisk INC | $125.98 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $116.55 | 2019-2021 | |
| Pfizer INC. | $102.84 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.44 | 2019-2021 | |
| Allergan, INC. | $80.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $41.53 | 2025 | Eliquis, Camzyos |
| Sanofi Pasteur INC. | $38.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $36.75 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $34.84 | 2025 | Fanapt |
| Gilead Sciences, INC. | $32.80 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.35 | 2020-2021 | |
| Amgen INC. | $29.11 | 2021-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $26.38 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $21.23 | 2025 | Neffy |
| Lundbeck LLC | $20.00 | 2025 | Rexulti |
| Roche Diagnostics Corporation | $18.37 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.23 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.97 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $16.95 | 2021 | |
| Exact Sciences Corporation | $16.46 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $11.65 | 2019 | |
| Mylan Specialty L.P. | $11.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Belete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.